Hengrui Pharmaceutical, BYD, COFCO Capital and other six companies issued important announcements
Breaking Announcement! Six companies, including Hengrui Pharmaceutical, BYD and COFCO Capital, issued important announcements.
i.Kingsoft Office: Announcement of the share repurchase plan through centralized bidding.
According to the company's announcement, the total amount of funds used for repurchase shall not be less than RMB 50 million (inclusive) and not more than RMB 10 million (inclusive); Repurchase** not more than RMB380 shares.
2. Zhejiang Construction Investment: The company's announcement on the receipt of the notice of winning the bid by the subsidiary.
Recently, Zhejiang Yijian Group is hereinafter referred to as"Zhejiang Yijian"Received the bidding announcement of Hangzhou Beixing Real Estate, Zhejiang Yijian successfully won the bid for Hangzhou Zhengzheng Reserve Plot XX project, and the winning bid price was 10200 million yuan. The winning bid was 102 billion RMB.
BYD: Announcement on the pledge of part of the shares of shareholders holding more than 5% of the shares.
According to the company's announcement, the company received a notice from Mr. Lv Xiangyang, a shareholder who holds more than 5% of the company's shares, that Mr. Lv has pledged part of the company's shares held by him. The total number of pledged shares is 4,186,000 shares, representing 0144%。
iv.COFCO Capital: Announcement on the abnormal fluctuation of the company's ** transactions.
The company announced that COFCO Capital Holdings*** hereinafter referred to as"company"**Trading** has accumulated deviations of 2140%, according to the relevant regulations of the Shenzhen ** Exchange, belongs to the ** abnormal fluctuation of trading. After self-analysis, there is no need to correct or supplement the information disclosed by the company in the early stage. Recently, there have been no major changes in the company's operating conditions and internal and external business environment, and it is expected that there will be no major changes.
v.Aerospace Development: Announcement of the largest shareholder and related parties to increase their shareholdings.
According to the company's announcement, China Aerospace System Engineering plans to raise funds of no more than RMB 200 million and not less than RMB 100 million; Aerospace Science and Industry Asset Management*** intends to raise funds of no more than RMB 100 million.
Hengrui Pharmaceutical: Announcement on obtaining the XX registration certificate.
The company announced that the company received the receipt of the XX Drug Administration (hereinafter referred to as the "hereinafter referred to as]"National Medical Products Administration"The approved "Drug Registration Certificate" approved the company's self-developed ticagrelor fumarate injection to be marketed for the use of **moderate to severe xx abdominal surgery.
Disclaimer: The above content does not constitute any advice or basis for buying or selling!